Prostate cancer patients who smoke may be more susceptible to complications from treatment, and have increased risk of side effects and disease recurrence.
This article reviews recent evidence suggesting an increased risk of pneumonia, cardiovascular disease, and acute kidney injury in men treated with ADT and consider whether the incidence of such events differs with the treatment modality.
As a variety of new hormonal agents are increasing survival times for men with metastatic disease, it is becoming increasingly important to consider cardiovascular, renal, and other potentially more serious risks associated with long-term ADT, especially in an aging population.
The problem with large sets of data is the risk of the “GIGO” principle—viz. garbage in, garbage out—and it requires a very careful and thoughtful investigator to rule out the many errors of large-scale data capture.
A small study found that testosterone may suppress the growth of some advanced prostate cancers and could reverse resistance to testosterone-blocking agents.
Dr. Morris discusses results and implications of the CHAARTED trial, which studied the survival impact of androgen deprivation therapy (ADT) plus docetaxel vs ADT alone for hormone-sensitive newly metastatic prostate cancer.
Dr. Bruce Roth, Siteman Cancer Center, spoke at the 2013 ASCO meeting about topics in seminoma. Here he discusses recurrence, relapse, and seminomatous vs nonseminomatous testicular cancer.
Dr. Bruce Roth, Professor of Oncology in the Division of Medicine at Siteman Cancer Center, Washington University at St. Louis, spoke at the 2013 ASCO meeting about topics in seminoma. Here he discusses the epidemiology of seminoma.
Dr. Bruce Roth discusses the large Danish study reported at ASCO (abstract 4502) that showed surveillance alone is sufficient after orchiectomy for stage I seminoma, focusing on its impact on post-surgery radiation therapy in this setting.
Following studies that found no survival or mortality benefit, we discuss the utility of primary androgen deprivation therapy in localized prostate cancer.
In this interview we discuss the role of early treatment, active surveillance, and watchful waiting in patients with PSA-detected early-stage prostate cancer.
![Subscribe to Genitourinary Cancers on [sitename]](http://www.cancernetwork.com/misc/feed.png){kind=small}
